Remission: What’s in a Name?

Abstract

Back to table of contents Previous article Next article Letter to the EditorFull AccessRemission: What’s in a Name?GARY REMINGTON, M.D., Ph.D., and SHITIJ KAPUR, M.D., Ph.D., GARY REMINGTONSearch for more papers by this author, M.D., Ph.D., and SHITIJ KAPURSearch for more papers by this author, M.D., Ph.D., Toronto, Ont., CanadaPublished Online:1 Dec 2005https://doi.org/10.1176/appi.ajp.162.12.2393-aAboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Nancy C. Andreasen, M.D., Ph.D., et al. (1) made a case for establishing “remission” criteria for schizophrenia, noting that this would provide a more homogeneous means of comparing outcome data. “Remission” was defined by the authors as a low level of symptoms that “do not influence an individual’s behavior” (p. 441).The criteria represent increased precision over such nonspecific descriptors as symptom improvement or stabilization, which could prove valuable as we seek to better understand schizophrenia, its course, and the use of various interventions. We laud this initiative and thank Dr. Andreasen et al. for their effort, although we disagree on what these criteria should be called. We are wary of reifying a decrease in a subset of symptoms without any reference or measure of real improvement in functional outcome or quality of life with the rather bold imprimatur of “remission.”The authors duly noted this limitation in their text because the criteria are confined to three dimensions of psychopathology (positive symptoms, negative symptoms, and disorganization) and did not address other domains (e.g., cognition, psychosocial symptoms) that are critical to functional recovery. They further added that “symptom quiescence” does not necessarily equate with functional improvement. The problem is that the majority of the specialists and lay users of this term from here on will not have the nuanced sophistication of its authors. This is more than semantic quibbling because nomenclature is not just a matter for psychiatric researchers anymore. It has implications for patients, families, direct-to-consumer advertising, insurance companies, governments, and societies at large.For the average person, remission implies that all explicit signs of the disease are gone and that the individual is now freed from illness to resume his or her natural trajectory in life. However, the patient with schizophrenia who, according to these criteria, would be in “remission” is likely to remain cognitively impaired, socially isolated, unemployed, and marginalized. Because all of these impairments are a direct consequence of the disease and its correlates, it would be unfair to say the illness is in remission. Indeed, both the individual and the family might be puzzled as well as frustrated in their daily struggle with the impact of the illness to hear that the medical profession has declared the same patient to be in remission. Remission could also be misinterpreted by insurance companies and payers working on the premise that symptomatic and functional improvement go hand in hand.We have been presented with clear criteria that define remission in certain important symptom domains; perhaps a label of “symptomatic remission” or some analog thereof may be more appropriate. Labels are powerful symbols; all we ask for is some deliberation on this point before the field adopts them.Reference1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162:441–449Link, Google Scholar FiguresReferencesCited byDetailsCited ByPersonal Recovery in Schizophrenia: A Narrative Review1 July 2022Comprehensive Psychiatry, Vol. 55, No. 5Early Intervention in Psychiatry, Vol. 7, No. 3The Personal Meaning of Recovery Among Individuals Treated for a First Episode of PsychosisDeborah Windell, M.Sc., Ross Norman, Ph.D., and Ashok K. Malla, M.B.B.S., F.R.C.P.C.1 June 2012 | Psychiatric Services, Vol. 63, No. 6Setting new standards in schizophrenia outcomes: Symptomatic remission 3years before versus after the andreasen criteria15 April 2020 | European Psychiatry, Vol. 27, No. 3Acta Psychiatrica Scandinavica, Vol. 126, No. 4Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment16 April 2020 | European Psychiatry, Vol. 25, No. 4CNS Drugs, Vol. 24, No. 1Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study26 June 2008 | Journal of Psychopharmacology, Vol. 23, No. 4Human Psychopharmacology: Clinical and Experimental, Vol. 24, No. 7Psychopharmacology, Vol. 202, No. 1-3Comprehensive Psychiatry, Vol. 50, No. 3The World Journal of Biological Psychiatry, Vol. 10, No. 4-2CNS Drugs, Vol. 21, No. 9 Volume 162Issue 12 December 2005Pages 2393-a-2394 Metrics PDF download History Published online 1 December 2005 Published in print 1 December 2005